Iowa City, IANCT03808922Now EnrollingIRB Ready

COVID-19 Clinical Trial in Iowa City, IA

Access cutting-edge covid-19 treatment through this phase 3 clinical trial at a research site in Iowa City. Study-provided care at no cost to qualified participants.

Sponsored by Ansun Biopharma, Inc.

Quick Self-Assessment

See if you qualify for this Iowa City location

Preparing your pre-screening questions…

Expert Care in Iowa City

Access covid-19 specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related covid-19 treatment provided free

Apply for This Iowa City Location

Check if you qualify for this covid-19 clinical trial in Iowa City, IA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Iowa City

    Convenient for IA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Iowa City site if eligible
  4. 4Begin participation

About This COVID-19 Study in Iowa City

This study will seek to enroll immunocompromised patients with Lower Tract parainfluenza infection. It also contains a sub-study to enroll patients with severe COVID-19.

Sponsor: Ansun Biopharma, Inc.

Who Can Participate

Inclusion Criteria

At the time of randomization, requires supplemental oxygen ≥2 LPM due to hypoxemia.
Immunocompromised, as defined by one or more of the following:
Received an autologous or allogeneic hematopoietic stem cell transplantation (HSCT) at any time in the past
Received a solid organ transplant at any time in the past
Has been or is currently being treated with chemotherapy for hematologic malignancies (e.g., leukemia, myeloma, lymphoma) and/or solid tumor malignancies (e.g., lung, breast, brain cancer) at any time in the past
Has an immunodeficiency due to congenital abnormality (only applicable to subjects age \< 18 years old) or pre-term birth (only applicable to subjects age ≤ 2 years old)
Has, within 3 days prior to randomization, a confirmed LRTI with a sialic acid dependent respiratory virus
If female, subject must meet one of the following conditions:
Not be of childbearing potential or
Be of childbearing potential and have a negative urine/serum pregnancy test and agrees to practice an acceptable method of contraception
Non-vasectomized males are required to practice effective birth control methods
Capable of understanding and complying with procedures as outlined in the protocol
Provides signed informed consent prior to the initiation of any screening or study-specific procedures For COVID-19 sub study:
Be ≥18 years of age
Provide adequate medical history to permit accurate stratification (but health status may be healthy, high-risk conditions, or immunocompromised).
Prior to SARS CoV 2 infection, has the ability to carry out self-care activities of daily living (basic ADL)
Have lower respiratory tract infection (LRTI) confirmed by CT imaging, with or without contrast, to involve at least 2 lobes of the lung.
Has laboratory-confirmation of the presence of SARS CoV 2 in the respiratory tract by at least one of the following samples
Satisfy inclusion criteria #1, 4, 5, 6, 7 of the main study

Exclusion Criteria

Subjects may not be on hospice care or, in the opinion of the investigator, have a low chance of survival during the first 10 days of treatment
Subjects with Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), or Alkaline Phosphatase (ALP) ≥3x ULN and Total Bilirubin (TBILI) ≥2x ULN Note: Subjects with ALT/AST/ALP ≥ 3x ULN AND TB ≥2x ULN that have been chronically stable (for \>1 year on more than one assessments) due to known liver pathology including malignancy (primary or metastasis), chronic medications, transplantation, or chronic infection will not be excluded
Female subjects breastfeeding or planning to breastfeed at any time through 30 days after the last dose of study drug
Subjects taking any other investigational drug used to treat pulmonary infection.
Psychiatric or cognitive illness or recreational drug/alcohol use that, in the opinion of the principal investigator, would affect subject safety and/or compliance
Subjects with known hypersensitivity to DAS181 and/or any of its components
Subjects with severe sepsis due to either their baseline SAD-RV infection or a concurrent viral, bacterial, or fungal infection and meet at least one of the following criteria:
Has evidence of vital organ failure outside of the lung (e.g., liver, kidney)
Requires vasopressors to maintain blood pressure For COVID-19 sub study:
Subjects requiring invasive mechanical, Bi-PAP or CPAP ventilation at randomization.
Subjects receiving any other investigational or empiric treatment for SARS-2-CoV (either as part of a clinical trial or under emergency approval (approved agents for the management of symptoms, e.g., fever, are permitted).
Subjects who are known HIV-positive (and not undetectable at most recent HIV RNA assessment)
Subjects who are currently taking immunomodulating biologics (e.g, interferons, interleukin)
Subjects with severe sepsis due to either their SARS-CoV-2 infection or a concurrent viral, bacterial, or fungal infection and meeting at least one of the following criteria:
Have evidence of vital organ failure outside of the lung (e.g., liver, kidney)
Require vasopressors to maintain blood pressure
Subjects meeting exclusion criteria #2, 3, 5 and 6 of the main study

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Iowa City?

Yes, this clinical trial (NCT03808922) has an active research site in Iowa City, IA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

COVID-19 Treatment Options in Iowa City, IA

If you're searching for covid-19 treatment options in Iowa City, IA, this clinical trial (NCT03808922) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Iowa City research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced covid-19 specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all covid-19 clinical trials near you to find additional studies recruiting in your area.

More COVID-19 Trials in Iowa City, IA

See all covid-19 clinical trials recruiting in Iowa City — not just this study.

Browse COVID-19 Trials in Iowa City →

Browse More Trials by Condition

COVID-19 TrialsAll Conditions →

Ready to Join in Iowa City?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Iowa City, IA